Gitanjali Ogawa
VP & Head of Investor Relations
Good afternoon. I’m Gita Jain, Head of Investor Relations, and thanks for becoming a member of us at the moment for Definium Therapeutics First Quarter 2026 Monetary Outcomes and Latest Highlights Convention Name. [Operator Instructions] This webcast is dwell on the Traders part of Definium’s web site at definiutx.com, and a replay will probably be out there after the webcast.
Main the decision at the moment will probably be Rob Barrow, our Chief Government Officer, who’s joined by Dr. Dan Karlin, our Chief Medical Officer; Brandi Roberts, our Chief Monetary Officer; and Matt Wiley, our Chief Industrial Officer.
Throughout at the moment’s name, we will probably be making sure forward-looking statements, together with, with out limitation, statements concerning the potential security, efficacy and regulatory and scientific progress of our product candidates, our anticipated money runway and our future expectations, plans, partnerships and prospects. These statements are topic to numerous dangers comparable to modifications in market circumstances and difficulties related to analysis and growth and regulatory approval processes.
These and different danger components are described within the filings made with the SEC
